Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of cisplatin + pemetrexed given before or after stereotactic radiotherapy in stage IB NSCLC
NL-OMON23245Phase 1Recruiting
- Sponsor
- prof. dr. EF Smit
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cisplatin and pemetrexed in non-small cell lung cancer (NSCLC), sponsored by prof. dr. EF Smit. Primary endpoint: Safety and feasibility of sequential chemotherapy and SRT. Started Feb 2009; status: recruiting.
02
Drugs
cisplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON23245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23245.